Alex Delaney-Gesing 

home

authors

alex-delaney-gesing

Michael R. Robinson, MD, vice president, Global Therapeutic Area Head, Ophthalmology at Allergan, an AbbVie company, discusses the results from a presentation titled, "Two Phase b Study Results for the Development of a Proprietary Formulation for the Treatment of Presbyopia," presented during the virtual AAO 2020 meeting.

Videos

Michael R. Robinson, MD, Allergan, discusses the results from a study analyzing an investigational ophthalmic solution for treatment of symptoms associated with presbyopia presented during the virtual AAO 2020 meeting.

Analysis of an investigational ophthalmic solution for treating presbyopia-related symptoms

's Sheryl Stevenson speaks with Dr Sunir J. Garg, co-director of retina research at the Wills Eye Hospital in Baltimore, Maryland, United States, on the highlights of his presentation at the 2021 annual American Academy of Ophthalmology (AAO) meeting regarding the impact of COVID-19 universal face masking on the risk of endophthalmitis following intravitreal anti-vascular endothelial growth factor (VEGF) injections.

The American Academy of Ophthalmology (AAO) annual meeting was held November 12 to 15 at the Ernest N. Morial Convention Centre in New Orleans, Louisiana, United States. The event included Subspecialty Days and a virtual component for remote participation.

Dr Sunir J. Garg speaks on the influence of COVID-19 universal face masking on the risk of endophthalmitis following intravitreal anti-VEGF injections.

Universal face masking reduces endophthalmitis incidence during anti-VEGF injections

Dr Justis P. Ehlers, The Norman C. and Donna L. Harbert Endowed Chair for Ophthalmic Research, Cole Eye Institute, Cleveland, Ohio, speaks with 

 Sheryl Stevenson on the findings from a higher-order OCT analysis for inflammatory signal biomarkers in the HAWK Study. 

Are there predictive factors that clinicians can identify in patients who may be more at risk for developing inflammation so that they can mitigate risk? 

Learn what this research may mean for clinicians and their patients.

The American Society of Retina Specialists (ASRS) is hosting its 39th Annual Scientific Meeting from 8-12 October 2021, at the JW Marriott San Antonio Hill Country Resort and Spa in San Antonio, Texas.

Dr Justis P. Ehlers discusses the findings from a higher-order OCT analysis for inflammatory signal biomarkers in the HAWK Study.

HAWK study: Higher order OCT analysis for inflammatory signal biomarkers

Biophytis has announced that it will begin recruiting patients in France and Belgium for the second part of the COVA Study analyzing Sarconeos (BIO101), its leading drug candidate, as a potential treatment for acute respiratory failure linked to COVID-19.

Along with Regulatory Authorities in Brazil and the U.S. 

providing authorization for the start of part 2 clinical trials

, authorization has also been obtained in France and Belgium to begin recruitment, according to a 

This follows the completion of enrollment for part 1 of the study, which includes 50 participants.

The COVA Study is a global, multi-center, double-blind, placebo-controlled, two-part phase 2-3 study assessing Sarconeos (BIO101), administered orally, in patients aged 45 and older who have been hospitalized with severe respiratory manifestations of COVID-19, the release stated.

The first part of the study targets preliminary data on the safety, tolerability and activity of Sarconeos (BIO101) in the trial’s participants. Interim analysis is tentatively expected later in this first quarter of this year, pending COVID-19 related delays or pandemic impacts, according to the company.

The second part of the COVA Study includes a phase 3 pivotal randomized study investigating the safety, efficacy of Sarconeos (BIO101) in the respiratory function of 310 COVID-19 patients (including the 50 patients from part 1 of the study), the company states. 

Complete results from both part 1 and part 2 of the study are expected in the second quarter of this year, pending any COVID-19-related delays, patient enrollment issues, or other interruptions.

Articles

Biophytis will begin recruiting patients in France and Belgium for the second part of the COVA Study analyzing its leading drug candidate as a potential treatment for acute respiratory failure linked to COVID-19.

Author | Alex Delaney-Gesing

Articles

Universal face masking reduces endophthalmitis incidence during anti-VEGF injections

HAWK study: Higher order OCT analysis for inflammatory signal biomarkers

Biophytis expands patient recruitment for part II of COVA Study in France, Belgium

Analysis of an investigational ophthalmic solution for treating presbyopia-related symptoms